TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

TORNTPHARM

37/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹4504.40-9.70(-0.21%)

Market Closed as of Jun 24, 2026, 15:30 IST

Select time range

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Smart Money: Smart money has been increasing their position in the stock.

Size: It is among the top 200 market size companies of india.

Balance Sheet: Reasonably good balance sheet.

Growth: Good revenue growth. With 43.7% growth over past three years, the company is going strong.

Past Returns: Outperforming stock! In past three years, the stock has provided 34.2% return compared to 8.8% by NIFTY 50.

Profitability: Recent profitability of 15% is a good sign.

Cons

No major cons observed.

Valuation
Market Cap	1.52 LCr
Price/Earnings (Trailing)	70.47
Price/Sales (Trailing)	10.98
EV/EBITDA	37.96
Price/Free Cashflow	64.98
MarketCap/EBT	53.08
Enterprise Value	1.66 LCr

Fundamentals
Revenue (TTM)	13.89 kCr
Rev. Growth (Yr)	42.1%
Earnings (TTM)	2.14 kCr
Earnings Growth (Yr)	-26.9%

Profitability
Operating Margin	21%
EBT Margin	21%
Return on Equity	12.16%
Return on Assets	4.82%
Free Cashflow Yield	1.54%

Growth & Returns
Price Change 1W	1.4%
Price Change 1M	-1.5%
Price Change 6M	18%
Price Change 1Y	41.6%
3Y Cumulative Return	34.2%
5Y Cumulative Return	25.6%
7Y Cumulative Return	28.6%
10Y Cumulative Return	21.2%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-12.71 kCr
Cash Flow from Operations (TTM)	3.02 kCr
Cash Flow from Financing (TTM)	10.15 kCr
Cash & Equivalents	1.12 kCr
Free Cash Flow (TTM)	2.35 kCr
Free Cash Flow/Share (TTM)	69.32

Balance Sheet
Total Assets	44.31 kCr
Total Liabilities	26.73 kCr
Shareholder Equity	17.59 kCr
Current Assets	9.39 kCr
Current Liabilities	8.34 kCr
Net PPE	4.91 kCr
Inventory	3.14 kCr
Goodwill	3.99 kCr

Capital Structure & Leverage
Debt Ratio	0.33
Debt/Equity	0.84
Interest Coverage	6.46
Interest/Cashflow Ops	8.85

Dividend & Shareholder Returns
Dividend/Share (TTM)	38
Dividend Yield	0.84%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Technical Indicators
RSI (14d)	66.02
RSI (5d)	77.4
RSI (21d)	46.65
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Shareholder Name	Holding %
TORRENT INVESTMENTS LIMITED (FORMERLY KNOWN AS TORRENT INVESTMENTS PRIVATE LIMITED)	68.31%
NPS TRUST	2.49%
Torrent Urja 39 Private Limited	0%
Torrent Urja 40 Private Limited	0%
Torrent Urja 41 Private Limited	0%
Torrent Urja 42 Private Limited	0%
Torrent Urja 43 Private Limited	0%
Torrent Urja 44 Private Limited	0%
Torrent Urja 45 Private Limited	0%
Torrent Urja 46 Private Limited	0%
Torrent Urja 47 Private Limited	0%
Dwarka Renewables Private Limited	0%
Azadirachta Indica Renewables Private Limited	0%
Onix-One Enersol Private Limited	0%
Torrent Gas Chennai Private Limited	0%
Torrent Gas Jaipur Private Limited	0%
Dholpur CGD Private Limited	0%
Radiant Urja LLP	0%
Abhivyakti Enterprise LLP	0%
Akalpya Enterprise LLP	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.41 LCr	60.43 kCr	+1.80%	+12.80%	38.46	7.3	-	-
CIPLA	Cipla	1.16 LCr	29.04 kCr	+1.70%	-4.10%	29.93	4	-	-
LUPIN	Lupin	1.08 LCr	28.38 kCr	+3.50%	+22.60%	20.28	3.81	-	-
DRREDDY	Dr. Reddy's Lab	1.06 LCr	35.06 kCr	-0.20%	-0.70%	25.24	3.03	-	-
AUROPHARMA	Aurobindo Pharma	88.9 kCr	34.18 kCr	+5.20%	+38.60%	25.37	2.6	-	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	21.4%	13,980	11,516	10,728	9,620	8,508	8,005
Other Income	-531.8%	-94	23	58	45	197	57
Total Income	20.3%	13,886	11,539	10,786	9,665	8,705	8,062
Cost of Materials	15.7%	1,758	1,520	1,657	1,480	1,538	1,421
Purchases of stock-in-trade	5.8%	1,619	1,531	1,184	1,089	831	1,005
Employee Expense	21.3%	2,671	2,203	1,984	1,678	1,526	1,440
Finance costs	53%	385	252	354	333	255	358
Depreciation and Amortization	40.8%	1,119	795	808	707	662	658
Other expenses	19.4%	3,362	2,816	2,690	2,365	2,108	1,933
Total Expenses	23.6%	10,925	8,842	8,522	7,818	6,994	6,536
Profit Before exceptional items and Tax	9.8%	2,961	2,697	2,264	1,847	1,711	1,526
Exceptional items before tax	-260%	-89	-24	88	0	-485	0
Total profit before tax	7.4%	2,872	2,673	2,352	1,847	1,226	1,526
Current tax	36.4%	844	619	462	374	342	327
Deferred tax	-178.2%	-110	143	234	228	107	-53
Total tax	-3.7%	734	762	696	602	449	274
Total profit (loss) for period	11.9%	2,138	1,911	1,656	1,245	777	1,252
Other comp. income net of taxes	-92.6%	-180	-93	17	-137	12	100
Total Comprehensive Income	7.7%	1,958	1,818	1,673	1,108	789	1,352
Earnings Per Share, Basic	13.4%	63.92	56.47	48.94	36.79	22.965	36.99
Earnings Per Share, Diluted	13.4%	63.92	56.47	48.94	36.79	0	36.99
Debt equity ratio	-	-	04	-	-	-	-
Debt service coverage ratio	-	-	0.0387	-	-	-	-
Interest service coverage ratio	-	-	0.1243	-	-	-	-

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	27.1%	4,197	3,303	3,302	3,178	2,959	2,809
Other Income	-28.6%	-17	-13	-27	-37	-18	33
Total Income	27.1%	4,180	3,290	3,275	3,141	2,941	2,842
Cost of Materials	36.8%	566	414	382	396	402	370
Purchases of stock-in-trade	13.1%	477	422	382	338	416	420
Employee Expense	21.1%	788	651	627	605	561	549
Finance costs	434.1%	236	45	48	56	56	57
Depreciation and Amortization	147.3%	508	206	204	201	201	199
Other expenses	35.7%	1,038	765	792	767	703	673
Total Expenses	45.4%	3,585	2,466	2,471	2,403	2,252	2,151
Profit Before exceptional items and Tax	-27.8%	595	824	804	738	689	691
Exceptional items before tax	-509.1%	-66	-10	-13	0	-24	0
Total profit before tax	-35.1%	529	814	791	738	665	691
Current tax	-32.1%	166	244	233	201	184	153
Deferred tax	97%	-1	-65	-33	-11	-17	35
Total tax	-7.9%	165	179	200	190	167	188
Total profit (loss) for period	-42.7%	364	635	591	548	498	503
Other comp. income net of taxes	-411.8%	-86	-16	-76	-2	36	-70
Total Comprehensive Income	-55.2%	278	619	515	546	534	433
Earnings Per Share, Basic	-40.9%	11.51	18.77	17.45	16.19	14.71	14.88
Earnings Per Share, Diluted	-40.9%	11.51	18.77	17.45	16.19	14.71	14.88
Debt equity ratio	-	-	-	-	-	04	-
Debt service coverage ratio	-	-	-	-	-	0.0491	-
Interest service coverage ratio	-	-	-	-	-	0.1366	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	10.6%	10,712	9,682	8,533	7,695	6,742	6,451
Other Income	-45.2%	18	32	91	82	204	118
Total Income	10.5%	10,730	9,714	8,624	7,777	6,946	6,569
Cost of Materials	3.2%	1,567	1,518	1,652	1,477	1,529	1,421
Purchases of stock-in-trade	4.8%	767	732	548	534	397	399
Employee Expense	14.9%	1,879	1,636	1,451	1,251	1,098	1,097
Finance costs	60.4%	341	213	303	298	236	339
Depreciation and Amortization	0.5%	764	760	761	672	602	610
Other expenses	10.6%	2,467	2,230	2,061	1,840	1,636	1,487
Total Expenses	9.6%	7,763	7,080	6,707	6,200	5,480	5,203
Profit Before exceptional items and Tax	12.6%	2,967	2,634	1,917	1,577	1,466	1,366
Exceptional items before tax	-184%	-70	-24	0	0	0	0
Total profit before tax	11%	2,897	2,610	1,917	1,577	1,466	1,366
Current tax	33.1%	720	541	322	274	253	248
Deferred tax	-108.9%	-15	181	238	251	222	-20
Total tax	-2.4%	705	722	560	525	475	228
Total profit (loss) for period	16.1%	2,192	1,888	1,357	1,052	991	1,138
Other comp. income net of taxes	-252.4%	-147	-41	31	-78	1	110
Total Comprehensive Income	10.7%	2,045	1,847	1,388	974	992	1,248
Earnings Per Share, Basic	16.4%	64.75	55.79	40.1	31.07	29.295	33.62
Earnings Per Share, Diluted	16.4%	64.75	55.79	40.1	31.07	29.295	33.62
Debt equity ratio	-	-	034	-	-	-	-
Debt service coverage ratio	-	-	0.0408	-	-	-	-
Interest service coverage ratio	-	-	0.1443	-	-	-	-

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	5.2%	2,735	2,599	2,762	2,616	2,433	2,377
Other Income	733.3%	58	-8	-27	-5	15	3
Total Income	7.8%	2,793	2,591	2,735	2,611	2,448	2,380
Cost of Materials	-7.6%	380	411	382	394	402	369
Purchases of stock-in-trade	6.1%	210	198	186	173	205	211
Employee Expense	1.7%	487	479	460	453	416	407
Finance costs	578.8%	225	34	37	45	47	48
Depreciation and Amortization	3.2%	197	191	189	187	190	191
Other expenses	15.4%	674	584	609	600	570	539
Total Expenses	18.1%	2,154	1,824	1,916	1,869	1,802	1,729
Profit Before exceptional items and Tax	-16.7%	639	767	819	742	646	651
Exceptional items before tax	-336.4%	-47	-10	-13	0	-24	0
Total profit before tax	-21.8%	592	757	806	742	622	651
Current tax	-69%	72	230	220	198	160	125
Deferred tax	202%	53	-50	-11	-7	-12	41
Total tax	-30.7%	125	180	209	191	148	166
Total profit (loss) for period	-19.1%	467	577	597	551	474	485
Other comp. income net of taxes	-916.7%	-60	-5	-55	-27	-5	-7
Total Comprehensive Income	-28.9%	407	572	542	524	469	478
Earnings Per Share, Basic	-20.2%	13.8	17.04	17.64	16.28	14	14.33
Earnings Per Share, Diluted	-20.2%	13.8	17.04	17.64	16.28	14	14.33
Debt equity ratio	-	-	-	-	-	034	-
Debt service coverage ratio	-	-	-	-	-	0.0511	-
Interest service coverage ratio	-	-	-	-	-	0.1528	-

Category	TORNTPHARM	Pharmaceuticals
PE	70.47	37.17
PS	10.98	5.10
Growth	20.3 %	10.7 %

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	80%	1,117	621	573	1,146	835	538
Current investments	883%	866	89	112	85	141	234
Loans, current	0%	5	5	5	4	3	3
Total current financial assets	74.5%	5,625	3,223	2,746	3,270	3,028	2,699
Inventories	27.2%	3,138	2,467	2,541	2,271	2,279	2,218
Total current assets	52.2%	9,392	6,171	5,623	5,879	5,611	5,272
Property, plant and equipment	42%	4,909	3,458	3,455	3,217	3,297	3,192
Capital work-in-progress	-6.4%	457	488	367	412	281	263
Investment property	-	13	0	0	-	-	0
Goodwill	1076.7%	3,990	340	339	339	338	337
Non-current investments	90.7%	83	44	44	42	32	43
Loans, non-current	-33.3%	3	4	3	3	3	2
Total non-current financial assets	74.3%	130	75	80	68	72	100
Total non-current assets	274.6%	34,919	9,323	9,367	9,209	9,450	9,457
Total assets	185.6%	44,312	15,515	14,990	15,088	15,061	14,744
Borrowings, non-current	1015.9%	11,651	1,045	1,192	1,414	1,604	2,110
Total non-current financial liabilities	818.1%	11,927	1,300	1,352	1,497	1,677	2,170
Provisions, non-current	41.5%	765	541	501	446	445	408
Total non-current liabilities	599%	18,384	2,631	2,682	2,737	2,779	3,139
Borrowings, current	103.8%	3,147	1,545	1,834	1,634	2,334	2,306
Total current financial liabilities	103%	7,547	3,719	4,077	4,144	4,728	4,362
Provisions, current	8.5%	499	460	408	435	400	405
Current tax liabilities	-7%	121	130	96	91	168	8
Total current liabilities	88.1%	8,343	4,435	4,717	4,847	5,426	4,898
Total liabilities	278.3%	26,727	7,066	7,399	7,584	8,205	8,037
Equity share capital	0%	169	169	169	169	169	169
Non controlling interest	-	9,196	-	0	-	-	0
Total equity	108.1%	17,585	8,449	7,591	7,504	6,856	6,707
Total equity and liabilities	185.6%	44,312	15,515	14,990	15,088	15,061	14,744

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	11.1%	71	64	105	91	105	81
Current investments	43.2%	127	89	112	85	141	234
Loans, current	0%	5	5	4	4	3	3
Total current financial assets	-1.9%	3,003	3,062	2,522	2,280	1,937	2,064
Inventories	2.2%	1,526	1,493	1,561	1,428	1,566	1,577
Total current assets	-1.2%	4,891	4,951	4,349	3,958	3,742	3,919
Property, plant and equipment	7.6%	3,336	3,101	3,132	3,132	3,205	3,113
Capital work-in-progress	-20.9%	384	485	365	247	204	235
Investment property	-	13	0	0	-	-	0
Goodwill	0%	324	324	324	324	324	324
Non-current investments	2864.8%	13,046	441	411	403	322	218
Loans, non-current	-33.3%	3	4	3	3	3	2
Total non-current financial assets	2763.8%	13,060	457	431	424	342	238
Total non-current assets	150.5%	20,922	8,353	8,493	8,450	8,635	8,704
Total assets	93.7%	25,814	13,325	12,842	12,408	12,377	12,623
Borrowings, non-current	1223.4%	11,462	867	1,021	1,414	1,604	1,944
Total non-current financial liabilities	1035.6%	11,641	1,026	1,104	1,442	1,620	1,963
Provisions, non-current	0.5%	368	366	338	289	282	260
Total non-current liabilities	486.9%	12,772	2,177	2,270	2,525	2,559	2,784
Borrowings, current	139.9%	2,702	1,127	1,526	1,127	1,729	1,733
Total current financial liabilities	88.3%	4,244	2,254	2,598	1,978	2,697	2,723
Provisions, current	-7.6%	219	237	207	210	171	172
Current tax liabilities	-50.4%	62	124	73	73	30	0
Total current liabilities	70.5%	4,590	2,693	2,980	2,357	2,989	2,974
Total liabilities	256.6%	17,362	4,870	5,250	4,882	5,548	5,758
Equity share capital	0%	169	169	169	169	169	169
Total equity	0%	8,452	8,455	7,592	7,526	6,829	6,865
Total equity and liabilities	93.7%	25,814	13,325	12,842	12,408	12,377	12,623

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	53%	385	252	353	333	255	-
Change in inventories	112.9%	35	-262	-49	256	219	-
Depreciation	40.8%	1,119	795	808	707	662	-
Unrealised forex losses/gains	-656.2%	-120	-15	-57	-49	-36	-
Adjustments for interest income	94.7%	38	20	11	0	0	-
Net Cashflows from Operations	20.2%	3,832	3,188	3,764	2,766	2,224	-
Income taxes paid (refund)	34.2%	809	603	498	398	421	-
Net Cashflows From Operating Activities	17%	3,023	2,585	3,266	2,368	1,803	-
Cashflows used in obtaining control of subsidiaries	-	12,315	0	0	1,941	0	-
Cash payment for investment in partnership firm or association of persons or LLP	-111.1%	0	10	0	0	0	-
Proceeds from sales of PPE	135.3%	41	18	134	159	6	-
Purchase of property, plant and equipment	10.8%	677	611	433	574	203	-
Interest received	84.2%	36	20	13	13	7	-
Other inflows (outflows) of cash	-200%	-8	-2	118	-13	-8	-
Net Cashflows From Investing Activities	-2250.1%	-12,713	-540	-168	-2,356	-198	-
Proceeds from borrowings	-	12,594	0	0	2,237	219	-
Repayments of borrowings	-27.5%	672	926	1,369	972	1,033	-
Payments of lease liabilities	107.7%	55	27	24	22	0	-
Dividends paid	19%	1,289	1,083	1,015	863	677	-
Interest paid	63.2%	427	262	371	303	258	-
Net Cashflows from Financing Activities	541.5%	10,151	-2,298	-2,779	77	-1,781	-
Effect of exchange rate on cash eq.	920%	83	-9	8	21	1	-
Net change in cash and cash eq.	306.5%	544	-262	327	110	-175	-

TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

TORNTPHARM

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

TORNTPHARM

TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

TORNTPHARM

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

TORNTPHARM

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Torrent Pharmaceuticals Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Torrent Pharmaceuticals Ltd. do?

Important Disclosure & Data Context